Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Efanesoctocog Alfa · Altuviiio, BIVV001

Fusion protein · Protein replacement: Neonatal Fc receptor (FCGRT) · developed by Bioverativ Therapeutics

Approved FDA
1 Registered trials

What is Efanesoctocog Alfa?

Efanesoctocog alfa is a recombinant factor VIII fusion protein carrying an Fc domain, the D'D3 domain of von Willebrand factor and two XTEN polypeptides. It temporarily replaces the missing coagulation factor VIII needed for clot formation, and its design extends circulating half-life. It is studied in hemophilia A (factor VIII deficiency).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Altuviiio, BIVV001, ALTUVIIIO
Drug type
Fusion protein
Targets
Neonatal Fc receptor (FCGRT) (binding partner it blocks)
Mechanism
Protein replacement: Neonatal Fc receptor (FCGRT)
Pathways
coagulation cascade, FcRn recycling pathway
Therapy area
Hematology
Developer
Bioverativ Therapeutics Inc.
In trials of
SNY
FDA status
Approved as Altuviiio, BLA125771 · FDA label
UNII
WH7BHQ0RB4

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06941870 Phase 4 Factor VIII Deficiency Recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Factor VIII Deficiency

Other drugs acting on FCGRT

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.